1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Surgiquest

Anonymous board for Surgiquest

Sort By:
Title
Replies Views
Last Message ↓
  1. Anonymous
    Replies:
    27
    Views:
    18,116
  2. Anonymous
    Replies:
    1
    Views:
    995
  3. anonymous
    Replies:
    2
    Views:
    3,169
  4. Anonymous
    Replies:
    52
    Views:
    21,753
  5. anonymous
    Replies:
    5
    Views:
    2,811
  6. Anonymous
    Replies:
    53
    Views:
    22,581
  7. Anonymous
    Replies:
    52
    Views:
    18,282
  8. Anonymous
    Replies:
    0
    Views:
    2,788
  9. Anonymous
    Replies:
    4
    Views:
    2,712
  10. Anonymous
    Replies:
    23
    Views:
    16,129
  11. Anonymous
    Replies:
    0
    Views:
    4,782
  12. Anonymous
    Replies:
    5
    Views:
    5,187

Thread Display Options

Loading...